PCSK9 and hyperlipidemia: Preclinical research suggests that PCSK9 suppresses HCV replication, which adds to the current interest in treating hyperlipidemia linked with HIV and antiretroviral therapy (ART) by inhibiting PCSK9 in HIV-infected individuals.